← All trials
NCT05591027
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2022
- Primary completion
- Oct 31, 2024
- Completion date
- Mar 31, 2025
- First posted
- Oct 24, 2022
- Last posted
- Oct 24, 2022
- Enrollment
- 48
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Oregon Health and Science UniversityOverall official - principal investigator
- Oregon Health and Science UniversityReponsible party - principal investigator
- Alzheimer's AssociationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.